In this context, our study aimed to evaluate the diagnostic performance of a panel of three genetic and epigenetic markers; HOXA9 gene promoter methylation, SOX2 and HV2 genes copy number variation in circulating cell free DNA in non-small cell lung cancer. This evidence concerns the gene HOXA9 and non-small cell lung carcinoma.